


PHARMACEUTICAL 2019

Checkpoint Therapeutics Inc. Rank 324 of 371









PHARMACEUTICAL 2019



Checkpoint Therapeutics Inc. Rank 324 of 371

The relative strengths and weaknesses of Checkpoint Therapeutics Inc. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Checkpoint Therapeutics Inc. compared to the market average is the variable Selling, General and Administrative Expense, increasing the Economic Capital Ratio by 79% points. The greatest weakness of Checkpoint Therapeutics Inc. is the variable Research and Development, reducing the Economic Capital Ratio by 444% points.

The company's Economic Capital Ratio, given in the ranking table, is -709%, being 378% points below the market average of -331%.

Input Variable	Value in 1000 USD
Assets, Current	24,899
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	13,093
Liabilities, Non-Current	0
Other Assets	0
Other Compr. Net Income	0
Other Expenses	0
Other Liabilities	0
Other Net Income	373
Property and Equipment	0
Research and Development	33,654
Revenues	3,506
Selling, General and Administrative Expense	6,592

Output Variable	Value in 1000 USD
Assets	24,899
Liabilities	13,093
Expenses	40,246
Stockholders Equity	11,806
Net Income	-36,367
Comprehensive Net Income	-36,367
Economic Capital Ratio	-709%

